<DOC>
	<DOCNO>NCT00370032</DOCNO>
	<brief_summary>This study look colonic mucosal blood flow subject take alosetron vs placebo healthy volunteer vs diarrhea-predominant Irritable Bowel Syndrome ( d-IBS ) patient .</brief_summary>
	<brief_title>Study Assess Effect Of Alosetron On Mucosal Blood Flow</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Alosetron</mesh_term>
	<criteria>Inclusion criterion : The subject sign date write informed consent form prior initiation studyrelated activity . The subject 18 49 year age time Screening Visit . The subject female either : A healthy subject . Healthy subject define individual free clinically significant illness disease determine medical history ( include family ) , physical examination , laboratory study , test . OR A dIBS patient per Rome II criterion normal result flexible sigmoidoscopy colonoscopy , flexible sigmoidoscopy plus barium enema , within 2 year Screening visit . The subject demonstrate negative urine pregnancy test result prior investigational product administration either : Of nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) postmenopausal define one year without menses absence hormone replacement therapy . sterilization ( via hysterectomy bilateral tubal ligation ) Of childbearing potential agrees one follow acceptable nonhormonal contraceptive method consistently accordance product label instruction physician . Subjects use effective contraceptive method least one month prior Screening continue use contraceptive method throughout study ( Followup Visit ) . Complete abstinence intercourse intrauterine device ( IUD ) insert qualified physician , provide IUD hormonal type publish data show high expected failure rate le 1 % per year ( IUDs meet criterion ) double barrier method comprise spermicide either condom diaphragm sterilization partner The subject ambulatory ( define depend exclusively wheelchair mobility ) . Exclusion criterion : The subject take oral contraceptive hormonal therapy . The subject concurrent illness disability may affect interpretation clinical data , otherwise contraindicate participation clinical study ( e.g. , unstable cardiovascular , autoimmune , renal , hepatic , pulmonary , endocrine , metabolic , gastrointestinal , hematologic , neurological condition ) . The subject constipationpredominant IBS ( cIBS ) alternate IBS per ROME II criterion . The subject current evidence history chronic severe constipation , history sequelae constipation . Evidence biochemical structural abnormality digestive tract . These condition include ( limited ) : Current evidence , history ( time past ) : GI/Bowel condition : inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) celiac disease laxative abuse ( clinical judgement physician ) gastrointestinal surgery ( exception include ≥6 month postsurgery appendectomy , cholecystectomy , fundoplication without gas bloat , hiatal hernia repair ; ≥3 month postsurgery herniorrhaphy without bowel resection ) gastroparesis GI malignancy carcinoid syndrome amyloidosis gastrointestinal adhesion ischemic colitis toxic megacolon impair intestinal circulation gastrointestinal perforation gastrointestinal obstruction and/or stricture Ischemic cardiovascular condition : coronary artery disease ( CAD ) significant atherosclerosis chronic pancreatitis diabetes thrombophlebitis hypercoagulable state . Current evidence ( within past 6 month ) : diverticulitis ileus symptomatic cholelithiasis proctitis . Current evidence : Hemoccult ( + ) stool . The subject BMI ≥27 . Mental impairment inability refusal follow direction . The subject current evidence , treat malignancy within past five year ( localize basal cell , squamous cell skin cancer cancer situ resect ) . The subject exhibit evidence hepatic dysfunction , viral hepatitis , exhibit serum ALT ( alanine aminotransferase ) ( SGPT ) , AST ( aspartate aminotransferase ) ( SGOT ) value &gt; 2.5 time upper limit normal alkaline phosphatase bilirubin value &gt; 2.0 time upper limit normal . The subject display renal impairment evidence serum creatinine value &gt; 2.0 mg/dl . The subject use medication within seven day prior dose , unless approve investigator GlaxoSmithKline ( GSK ) personnel . Section 9.1 . The subject use investigational drug , participate investigational study , within 30 day Screening Visit . The subject history drug allergy ( include limit hypersensitivity response alosetron , opinion investigator , contraindicate subject 's participation study . Subjects make blood donation ( &gt; 450mL ) within 6 week prior screen . The subject history alcohol and/or substance abuse within past two year . The subject pregnant . The subject breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>mucosal blood flow d-IBS</keyword>
</DOC>